Citius Pharma discontinues obesity drug Suprenza to focus on core assets

4 July 2016

US specialty pharma company Citius Pharmaceuticals (OTC BB: CTXR) revealed today it was discontinuing Suprenza, its FDA-approved phentermine-based product for weight loss. The news pushed Citius’ shares 4.49% lower to $0.85 on Friday.

Myron Holubiak, chief executive of Citius, said: "Suprenza no longer meets our core strategic objectives. We are dedicating our focus on our Phase III asset Mino-Lok and our Phase IIb asset Hydro-Lido for hemorrhoids."

Mr Holubiak continued: "We feel that the obesity and weight management market has shifted and therefore we are devoting our efforts on developing our leading two assets. We anticipate a minimal financial impact to Citius from discontinuation since we eliminate our ongoing regulatory expenses and have not historically received royalties from the product."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK